Ceribell, Inc. (CBLL) recently announced that it has received FDA clearance for the Clarity algorithm for use in pediatric patients. This breakthrough expands the utility of Ceribell’s rapid electroencephalography (“EEG”) system, enabling faster seizure detection and treatment in critically ill children.With this clearance, Ceribell strengthens its position in the neurodiagnostic space by addressing a critical gap in pediatric care. The Clarity algorithm is designed to support timely clinical decisions, imp ...